An Open Label Study to Evaluate G17DT Compared to Gemcitabine
Status:
Completed
Trial end date:
2002-09-19
Target enrollment:
Participant gender:
Summary
In this study 250 µg of G17DT was administered at Weeks 0, 2 and 6 in order to demonstrate
non inferiority compared to gemcitabine in prolonging survival in advanced pancreatic cancer.